阿瑞匹坦治疗表皮松解症和特应性皮炎患者难治性瘙痒症的疗效：一项回顾性研究。

IF 1.2 4区医学 Q3 DERMATOLOGY

Pediatric Dermatology Pub Date : 2024-07-25 DOI:10.1111/pde.15704

Cheryl J Hartzell, Alexandra Szabova, Andrew B Collins, Armand N Morel, Desimir Mijatovic, Kenneth R Goldschneider

{"title":"阿瑞匹坦治疗表皮松解症和特应性皮炎患者难治性瘙痒症的疗效：一项回顾性研究。","authors":"Cheryl J Hartzell, Alexandra Szabova, Andrew B Collins, Armand N Morel, Desimir Mijatovic, Kenneth R Goldschneider","doi":"10.1111/pde.15704","DOIUrl":null,"url":null,"abstract":"Introduction: At a single-center pediatric hospital, the neurokinin-1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD).Methods: Thirty-seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years.Results: 58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age-related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use.Conclusions: Aprepitant shows promise in controlling refractory pruritus in pediatric EB and AD patients and deserves further study.","PeriodicalId":19819,"journal":{"name":"Pediatric Dermatology","volume":null,"pages":null},"PeriodicalIF":1.2000,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study.\",\"authors\":\"Cheryl J Hartzell, Alexandra Szabova, Andrew B Collins, Armand N Morel, Desimir Mijatovic, Kenneth R Goldschneider\",\"doi\":\"10.1111/pde.15704\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Introduction: At a single-center pediatric hospital, the neurokinin-1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD).Methods: Thirty-seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years.Results: 58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age-related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use.Conclusions: Aprepitant shows promise in controlling refractory pruritus in pediatric EB and AD patients and deserves further study.\",\"PeriodicalId\":19819,\"journal\":{\"name\":\"Pediatric Dermatology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.2000,\"publicationDate\":\"2024-07-25\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Dermatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1111/pde.15704\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Dermatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1111/pde.15704","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

简介：在一家单中心儿科医院，神经激肽-1受体拮抗剂阿瑞匹坦被用于治疗表皮松解症（EB）和特应性皮炎（AD）的难治性瘙痒症：方法：纳入37名患者（24名EB患者，13名AD患者），年龄在10个月至37岁之间：58%（14/24）的EB患者和85%（11/13）的AD患者表示阿瑞匹坦能够有效减轻他们的瘙痒症状，在EB患者中观察到与年龄相关的疗效差异，保险拒保或药物供应不足阻碍了药物的使用：阿瑞匹坦有望控制儿童 EB 和 AD 患者的难治性瘙痒，值得进一步研究。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Efficacy of aprepitant for refractory pruritus in patients with epidermolysis bullosa and atopic dermatitis: A retrospective study.

Introduction: At a single-center pediatric hospital, the neurokinin-1 receptor antagonist aprepitant was used to treat refractory pruritus in epidermolysis bullosa (EB) and atopic dermatitis (AD).

Methods: Thirty-seven patients were included (24 EB patients, 13 AD patients), ages 10 months to 37 years.

Results: 58% (14/24) of patients with EB and 85% (11/13) of patients with AD reported aprepitant was effective in decreasing their pruritus, with age-related differences in efficacy observed in EB patients, and access to the medication by insurance denial or availability of the drug as a barrier to use.

Conclusions: Aprepitant shows promise in controlling refractory pruritus in pediatric EB and AD patients and deserves further study.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pediatric Dermatology 医学-皮肤病学

CiteScore

3.20

自引率

6.70%

发文量

269

审稿时长

1 months

期刊介绍： Pediatric Dermatology answers the need for new ideas and strategies for today''s pediatrician or dermatologist. As a teaching vehicle, the Journal is still unsurpassed and it will continue to present the latest on topics such as hemangiomas, atopic dermatitis, rare and unusual presentations of childhood diseases, neonatal medicine, and therapeutic advances. As important progress is made in any area involving infants and children, Pediatric Dermatology is there to publish the findings.